Form 4: Redmile Group Acquires IGM Biosciences Stock as Part of Director Compensation

Redmile Group, through its managing director Michael Lee, received 1,734 shares of IGM Biosciences common stock as part of a quarterly retainer, while also ceasing to manage an account holding 120,347 shares.

Summary

• Redmile Group, a significant shareholder in IGM Biosciences, acquired 1,734 shares of common stock on December 31, 2024.
• These shares were granted as part of a quarterly retainer to Michael Lee, a managing director at Redmile and a member of IGM Biosciences' board.
• The shares were granted as fully vested restricted stock units, each representing one share of IGM Biosciences common stock.
• Redmile, through Michael Lee, holds a total of 2,963,187 shares of IGM Biosciences after this transaction.
• Redmile has ceased serving as the investment advisor to a sub-advised account that held 120,347 shares of IGM Biosciences, and therefore no longer has voting or dispositive power over those shares.
• Jeremy Green, the principal of Redmile, may also be deemed to beneficially own the reported securities.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation and a change in managed accounts. It is neither overly positive nor negative, indicating a neutral to slightly positive sentiment due to continued alignment.

Positives

• The acquisition of shares through director compensation indicates continued alignment between Redmile and IGM Biosciences.
• The grant of fully vested restricted stock units suggests a long-term commitment from Redmile.

Negatives

• Redmile ceasing to manage an account holding 120,347 shares could be seen as a slight reduction in their overall influence.

Risks

• The document does not explicitly state any risks, but changes in investment management can sometimes indicate shifts in strategy or confidence.

Management Comments

• Michael Lee holds the securities as a nominee on behalf of Redmile and has assigned all economic, pecuniary and voting rights to Redmile.
• Redmile and Jeremy Green disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a major shareholder and director, which is common in the biotech industry.

Comparison to Industry Standards

• Similar filings are common for directors and major shareholders in publicly traded companies, especially in the biotech sector where stock-based compensation is prevalent.
• The transaction is typical for director compensation, often involving restricted stock units that vest over time or upon certain conditions.
• The cessation of managing a sub-advised account is not unusual and can occur due to various reasons, such as changes in investment strategy or client relationships.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows continued alignment between a major shareholder and the company.
• The change in managed shares is unlikely to have a significant impact on other stakeholders.

Key Dates

Keywords

Redmile Group, IGM Biosciences, stock acquisition, director compensation, beneficial ownership, restricted stock units, investment management